An Investigational New Drug Application (IND) is a request for authorization from the Food and Drug Administration (FDA) to administer an investigational drug or biological product to humans. Following preclinical benchwork, conducting investigations under an IND is the first step to getting a new drug approved for marketing by the FDA.
Not all clinical studies need to operate under an IND. Use the decision tree to determine whether a proposed investigation will require IND submission and FDA oversight.
Preparing an IND submission can seem daunting. Downloadable templates and detailed descriptions of IND submission documents can help simplify the task. The initial IND submission to the FDA will provide the reviewers with the information necessary to conduct a thorough evaluation of the safety of the investigation, and its scientific merit. The submission is divided into several sections. The summaries listed in this page will provide detailed instructions to prepare a complete IND submission.
After the IND submission has been delivered to the FDA, it undergoes a review process and there are several possible outcomes that can occur. This page itemizes potential FDA responses and the steps an investigator should take in each situation.
Once an IND submission has been approved, the FDA still requires periodic updates to evaluate the continued safety of the investigation. The Principal Investigator is responsible for notifying the FDA of any changes to the study protocol, site(s), or principal investigator. Some changes require approval prior to implementation. Additionally, any serious adverse events should be reported. This page details the actions that need to be taken to maintain an IND submission with the FDA.
Bringing an investigational drug from bench to bedsite is a long, complicated process involving many nonclinical and clinical investigations and layers of regulatory oversight. This page will provide an easy-to-follow timeline for the life cycle of a new drug and detailed descriptions for the whole process.